Suven Pharma inks pact with CSIR-IICT for process technology transfer of Molnupiravir

Suven Pharmaceuticals Limited (SPL) announced that it has entered into an agreement for the process technology transfer & manufacturing of the anti-COVID drug, Molnupiravir, and 2-DG with CSIR Indian Institute of Chemical Technology (CSIR-IICT) and CSIR National Institute of Interdisciplinary Science & Technology (CSIR-NIIST).   

Molnupiravir is an antiviral drug developed for the treatment of influenza and has been repurposed to completely suppress the COVID virus transmission within 24 hours, according to the study recently published in the journal, Nature Microbiology.  

The agreements involve a total fee of Rs 8 lakh plus taxes for the non-exclusive grant of the licences to SPL. The process and know-how of the drug were sourced from CSIR-NIIST while the scale-up process was successfully carried out by CSIR-IICT. The agreement will enable SPL to manufacture and launch in the domestic market as an effective medication for COVID-infected patients, subject to regulatory approvals.  

At 12.44 pm on Friday, the company’s stock was trading at Rs 490.70, up by 2.05 per cent on BSE.